<DOC>
	<DOCNO>NCT00256854</DOCNO>
	<brief_summary>This multi-center , Phase III study evaluate safety tolerability propose dose conversion recommendation RLS subject convert ropinirole immediate release ropinirole controlled-release RLS .</brief_summary>
	<brief_title>Converting From Ropinirole Immediate Release ( IR ) To Ropinirole Controlled-Release RLS ( Restless Legs Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Diagnosis RLS use IRLS Study Group ( IRLSSG ) diagnostic criterion . Subjects currently treat RLS stable dose ( least 2 week ) ropinirole IR give daily . Subjects RLS symptom even night night time . Subjects give write informed consent participate . Subjects require treatment daytime RLS symptom . Signs secondary RLS , serum ferritin level le 10 mcg/L . Movement Disorders , Clinically significant unstable medical condition . Abnormal lab , electrocardiogram ( ECG ) physical finding . Receiving prohibited medication . Sleeping habit incompatible study design . Intolerance ropinirole dopamine agonist . Pregnant lactating . Women childbearing potential practicing acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RLS</keyword>
	<keyword>Ropinirole</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>